ForrestBrown

Key points Overall increase in the amount of R&D tax relief claimed to £8.2 billion. While the total benefit increases, claim volume declines by 17%. Large companies claim more in value than SMEs for the first time. HMRC has today published its annual sta

Key takeaways Annual Patent Box statistics indicate an increase in both the number of companies electing into the regime and the value of the relief. Large businesses, manufacturing and London-based companies continue to dominate, though regional pockets

Key points HMRC launches new promotional material on R&D tax credits. The material is aimed at SMEs and points to useful resources to help inform R&D decision making. At the end of July, HMRC released new "promotional material" on R&D tax credits, titled

Summary Businesses consider switching R&D tax provider for many reasons, including increased provider fees, technical errors, a lack of proactivity, drop in service standards, and reduced claim value. There are key considerations around switching provider

It can be hard to know what good service looks like when it comes to R&D tax relief. Bad service is a lot easier to spot. The quality of service you receive has a significant impact on the value of your R&D claim and its robustness, but also the overall e

HMRC annual report and accounts: key points Error and fraud in R&D claims has declined and is projected to fall further. Declining rate attributed to operational and legislative changes. While the figures point to a welcome period of stability for the inc

Patent Box compliance - key points Patent Box is a growing area of focus for HMRC. Developments such as the introduction of GfC9 - Patent Box suggest this may result in an uptick in compliance activity. Businesses should be prepared and ensure they protec

Key points HMRC's volume compliance approach to R&D enquiries, run by ISBC, will end. The approach resulted in more enquiries, but a corresponding slow-down in the time taken to resolve them. The Wealthy and Mid-sized Business Compliance (WMBC) Directorat

"I've always enjoyed working with people who want to solve problems", says Oli Rayner, Co-Founder and CEO of Gramics Bio. Established in 2024, under the name 'Panthura', Gramics Bio is on a mission to engineer a new class of gene therapy to unlock disease

Our technical specialists are passionate about R&D, not just at work, but in their private lives too. In part two of our mini-series shining a light on the projects our experts work on in their spare time, technical manager, Robert Lutken, discusses devel